Shares of Gland Pharma Ltd surged 3.34% to ₹1,548.30 on Wednesday, following the company’s Q4 FY25 results. Despite a decline in profit and sales, investor sentiment remained upbeat, possibly buoyed by a stable margin profile and a healthy dividend announcement.
The company reported a consolidated net profit of ₹186.54 crore for the quarter ended March 2025, down 3.06% from ₹192.42 crore in the same quarter last year. Revenue from operations dropped 7.32% year-on-year to ₹1,424.91 crore compared to ₹1,537.45 crore in Q4 FY24.
Operating profit margin stood at 24.39% for the quarter, slightly higher than the 23.33% recorded in the year-ago period, indicating improved cost efficiencies. Total expenses for the quarter declined to ₹1,180.61 crore from ₹1,281.37 crore.
For the full financial year, net profit fell 9.57% to ₹698.53 crore, while annual revenue declined marginally by 0.85% to ₹5,616.50 crore.
Geographically, revenue from the US, Gland’s largest market, fell 10% to ₹791.8 crore. Revenue from Europe rose 4% to ₹280.2 crore, and India remained flat at ₹52.5 crore. Other markets such as Canada, Australia, and New Zealand also saw a 4% increase to ₹60.1 crore.
The company’s board recommended a final dividend of ₹18 per equity share for FY25, subject to shareholder approval.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
